<div id="readability-page-1"><div>By Katherine Hamilton Johnson &amp; Johnson's Rybrevant Faspro was approved as a treatment for people with lung cancer by the Food and Drug Administration. Rybrevant Faspro was approved across all indications for subcutaneous administration for patients with epidermal growth factor receptor-mutated non-small cell lung cancer, J&amp;J said Wednesday. The approval is based on the results of a Phase 3 trial, which met both co-primary pharmacokinetic endpoints. Patients treated showed longer duration of response, improved progression-free survival and longer overall survival. Rybrevant Faspro enables a simpler, shorter administration time for a first-line combination regime when combined with Lazcluze. Rybrevant is approved in the U.S. across four indications in that specific type of lung cancer. Write to Katherine Hamilton at katherine.hamilton@wsj.com (END) Dow Jones Newswires12-17-25 1920ET</div></div>

強生

強生的 Rybrevant Faspro 獲得 FDA 批准，用於治療表皮生長因子受體突變的非小細胞肺癌。該批准基於成功的第三階段臨牀試驗結果，顯示出改善的生存率和反應持續時間。Rybrevant Faspro 與 Lazcluze 聯合使用時提供了更簡單的給藥方式，並在美國獲得了四項適應症的批准

強生公司獲得美國食品藥品監督管理局批准其肺癌治療方案